HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Conditions: Fanconi Anemia; Severe Marrow Failure; Myelodysplastic Syndrome (MDS); Acute Myelogenous Leukemia (AML)Interventions: Drug: Busulfan; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: rabbit ATG; Drug: G-CSF; Biological: Peripheral blood stem cellSponsors: Children's Hospital Medical Center, Cincinnati; Memorial Sloan Kettering Cancer CenterRecruiting - verified April 2015

http://clinicaltrials.gov/ct2/show/NCT02143830?lup_s=04%2F05%2F2015&lup_d=30

Source: ClinicalTrials.gov - April 28, 2014 Category: Research Source Type: clinical trials